dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Dasari, Arvind |
dc.contributor.author | Sobrero, Alberto |
dc.contributor.author | Yao, James |
dc.contributor.author | Schelman, William |
dc.contributor.author | Yang, Zhao |
dc.contributor.author | Tabernero Caturla, Josep |
dc.contributor.author | Yoshino, Takayuki |
dc.date.accessioned | 2022-02-22T09:29:30Z |
dc.date.available | 2022-02-22T09:29:30Z |
dc.date.issued | 2021-08 |
dc.identifier.citation | Dasari A, Sobrero A, Yao J, Yoshino T, Schelman W, Yang Z, et al. FRESCO-2: a global Phase III study investigating the efficacy and safety of fruquintinib in metastatic colorectal cancer. Futur Oncol. 2021 Aug;17(24):3151–3162. |
dc.identifier.issn | 1479-6694 |
dc.identifier.issn | 10.2217/fon-2021-0202 |
dc.identifier.uri | https://hdl.handle.net/11351/7060 |
dc.description | Desenvolupament clínic; Fruquintinib; Càncer colorrectal metastàtic refractari |
dc.language.iso | eng |
dc.publisher | Future Science Group |
dc.relation.ispartofseries | Future Oncology;17(24) |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
dc.source | Scientia |
dc.subject | Recte - Càncer - Tractament |
dc.subject | Còlon - Càncer - Tractament |
dc.subject | Avaluació de resultats (Assistència sanitària) |
dc.subject.mesh | Colorectal Neoplasms |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Antineoplastic Agents |
dc.subject.mesh | Treatment Outcome |
dc.title | FRESCO-2: a global Phase III study investigating the efficacy and safety of fruquintinib in metastatic colorectal cancer |
dc.type | info:eu-repo/semantics/article |
dc.subject.decs | neoplasias colorrectales |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | antineoplásicos |
dc.subject.decs | resultado del tratamiento |
dc.relation.publishversion | https://doi.org/10.2217/fon-2021-0202 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Dasari A, Yao J] Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 426, Houston, TX 77030, USA. [Sobrero A] Ospedale Policlinico San Martino – IRCCS, Largo R. Benzi n.10, Ospedale Policlinico San Martino, Padiglione ex Microbiologia, Piano Terra Levante, 16132, Genova, Italy. [Yoshino T] Department of Gastroenterology & Gastrointestinal Oncology, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa, Chiba, 270-8577, Japan. [Schelman W] Clinical Development, Hutchison MediPharma International Incorporated, 25A Vreeland Road, Suite 304, Florham Park, NJ 07932, USA. [Yang Z] Biostatistics, Hutchison MediPharma International Incorporated, 25A Vreeland Road, Suite 304, Florham Park, NJ 07932, USA. [Tabernero J] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. IOB-Quiron, UVic-UCC, Barcelona, Spain |
dc.identifier.pmid | 33993740 |
dc.identifier.wos | 000651079000001 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |